SCHEMBL500093

SCHEMBL500093

CC1CN(CCC(=O)O)CCO1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.53
KDM1A O60341 1/20 0.43
DRD1 P21728 1/20 0.41
PDK1 Q15118 1/20 0.41
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38
HSD17B10 Q99714 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
GLRA1 P23415 1/20 0.35
WNT1 P04628 1/20 0.34
GSK3B P49841 1/20 0.34
DYRK1A Q13627 1/20 0.34
CYP1A2 P05177 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 2/20 0.34
ALDH1A1 P00352 1/20 0.34
MAPT P10636 1/20 0.34
APEX1 P27695 1/20 0.34
DRD3 P35462 2/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715037 0.82 HSD17B10 (0.50) GLAKDM1ADRD1PDK1HSD17B10
SCHEMBL28864627 0.82 HSD17B10 (0.50) GLAKDM1ADRD1PDK1HSD17B10
SCHEMBL28864611 0.82 HSD17B10 (0.50) GLAKDM1ADRD1PDK1HSD17B10
SCHEMBL28130134 0.82 SMN1; SMN2 (0.48) GLAKDM1ADRD1PDK1SMN1; SMN2
SCHEMBL28141848 0.81 PDK1 (0.39) GLAKDM1ADRD1PDK1ALDH1A1
Hydrochloric Acid SCHEMBL5092822 0.81 HSD17B10 (0.48) GLAKDM1ADRD1PDK1HSD17B10
SCHEMBL500357 0.80 GLA (0.50) GLAOPRM1OPRD1HSD17B10SMN1; SMN2
SCHEMBL12331035 0.79 GLA (0.53) GLAPDK1OPRM1OPRD1HSD17B10
Acetic Acid SCHEMBL28685632 0.79 EBP (0.44) KDM1ADRD1PDK1KMT2AALDH1A1
SCHEMBL12206843 0.79 GLA (0.49) GLAOPRM1OPRD1HSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103980204-B Ionic liquid-catalyzed amine and α, β-unsaturated electron deficiency receptor method TAIZHOU UNIVERSITY (CN) 2016-03-30 CN disclosed
CN-103980204-A Method for catalyzing amines and alpha, beta-unsaturated electron-deficient acceptors by ionic liquid UNIV TAIZHOU 2014-08-13 CN disclosed
US-20130060013-A1 Compounds useful for treating neurodegenerative disorders SATORI PHARMACEUTICALS, INC. (US) 2013-03-07 US disclosed
US-8105760-B2 Patterning process and pattern surface coating composition SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-01-31 US disclosed
US-20110251379-A1 COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS SATORI PHARMACEUTICALS, INC. (US) 2011-10-13 US disclosed
CN-1947066-B Rinse solution for lithography TOKYO OHKA KOGYO CO LTD 2011-04-13 CN disclosed
US-20090053657-A1 PATTERNING PROCESS AND PATTERN SURFACE COATING COMPOSITION SHIN-ETSU CHEMICAL CO., LTD. (JP) 2009-02-26 US disclosed
CN-101010640-A Developing solution composition for lithography and method for resist pattern formation TOKYO OHKA KOGYO CO LTD (JP) 2007-08-01 CN disclosed
CN-1947066-A Rinse solution for lithography TOKYO OHKA KOGYO CO LTD (JP) 2007-04-11 CN disclosed
US-20050282387-A1 Metal polish composition, polishing method using the composition and method for producing wafer using the polishing method SHOWA DENKO K.K. (JP) 2005-12-22 US disclosed
EP-1517972-A1 METAL POLISH COMPOSITION, POLISHING METHOD USING THE COMPOSITION AND METHOD FOR PRODUCING WAFER USING THE POLISHING METHOD Showa Denko K.K. (JP) 2005-03-30 EP disclosed
WO-2003104350-A1 METAL POLISH COMPOSITION, POLISHING METHOD USING THE COMPOSITION AND METHOD FOR PRODUCING WAFER USING THE POLISHING METHOD SHOWA DENKO K.K. (JP) 2003-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130060013-A1 Compounds useful for treating neurodegenerative disorders SNCA, HTT, CLN6 GLA 330/4885KDM1A 3542/4885DRD1 2209/4885
US-20110251379-A1 COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS CLN6, NLN, ACHE GLA 191/4885KDM1A 2863/4885DRD1 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.